EUCTR2011-000567-26-NL进行中（未招募）1 期
A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents. - CONCA
Radboud University Medical Centre Nijmegen0 个研究点目标入组 264 人开始时间: 2012年4月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible to be included in the study only if they meet all of the inclusion criteria below.
- •- Male or female patients aged 6.0 - <17.0 years at Visit 1.
- •- Patients must have an IQ of > 85 (based on, e.g., 4 WISC subtests): vocabulary, similarities, block design, and matrix reasoning (cf. Crawford et al., 2010. Age- and country-specific adaptations will be used.
- •- Patients must meet DSM-IV-TR diagnostic criteria for DSM-IV-TR Conduct Disorder(s) as confirmed by the Kiddie-SADS, Conduct Disorder Module: 312.8x. (Kaufman et al., 1996) both at Visit 2 and Visit 3.
- •- Patients must score = 27 on the Nisonger CBR Form, ODD/CD Disruptive Behavior Composite (D-Total) either at Visit 2 or Visit 3.
- •- Patients must score =4 (moderately ill” (or > 5, markedly ill”) on the CGI-S rating scale at Visits 2 and 3.
- •- If a female of child-bearing potential, patients must test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agree to use a reliable method of birth control. (Adequate contra- ception includes: oral contraceptives, intraueterine devices; double barrier method (diaphragm or condom plus spermicide), Norplant™ or Depot Provera™)).
- •- Patients must have a body weight of at least 25 kg at study entry.
- •- Patients must be able to swallow study drug.
- •- Patients must have venous access sufficient to allow blood sampling and are compliant with blood draws as per protocol
- •- Subjects’ parents/legal guardians must provide and sign informed consent documents; patients must provide informed consent, and sign consent or assent documents if capable, according to the legal requirements in the very country.[11] A reliable person (primary caregiver, parent) must be available to ensure compliance with study procedures throughout the course of the study.
- •- Patients meeting criteria for comorbid ADHD (as to the clinical judgment of the investigator) will not be excluded from study participation.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 39
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient will be excluded from the study if he or she meets any exclusion criteria described below, according to the assessment of the investigator.
- •- Is immediate family of investigator site personnel directly affiliated with this study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •- Has been treated with a drug within 14 days before Visit 1 that has not received regulatory approval for any indication at the time of study entry.
- •- Has participated in any investigational drug trial within six months prior to baseline (visit 3).
- •- Has previously completed or withdrawn from this study or any other study investigating risperidone or has previously been identified as being a nonresponder or intolerant of risperidone.
- •- Has a current (within 6 months of the start of the study) or lifetime DSM-IV-TR diagnosis of schizophrenia-related disorders, schizophrenia, bipolar disorder, major depressive disorder, or current substance dependence disorder (given the nature of the study population substance misuse or abuse is not exlusionary), pervasive developmental disorder (autistic disorder or Asperger disorder).
- •- In the clinical judgment of the investigator, meets criteria for a primary psychiatric disorder, e.g., Anxiety Disorder, Depressive Disorder, Tic Disorder or Tourette’s Syndrome (comorbid ADHD is permitted, cf. Incl. criteria section)
- •- Starts any psychotropic medication, including health-food supplements that the investigator feels could have central nervous system activity (for example, St. John’s Wort, melatonin), during the course of the study, or is taking any other excluded concomitant medication(s) at/beyond Visit 2 (specified in Section 5.7). (An ongoing long-term medication, e.g., to treat a comorbid disorder such as ADHD, is permitted as long as compound and dose are not changed throughout the course of the study.)
- •- Has any acute or unstable medical condition, physiological condition, clinically significant laboratory, or ECG results that, in the opinion of the investigator, would compromise participation in the study.
- •- Has a known or suspected seizure disorder.
- •- Has a history of neuroleptic malignant syndrome (NMS) or of tardive dyskinesia.
- •- Has a history of hypersensitivity to neuroleptics, of tardive dyskinesia, or neuroleptic malignant syndrome.
- •- Is pregnant or nursing.
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer.HR+, HER2- advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2013-003084-61-ATovartis Pharma Services AG650
已完成
3 期
A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM).10027656NL-OMON37228ovartis21
进行中（未招募）
不适用
A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)MedDRA version: 9.1Level: LLTClassification code 10051810Term: AngiomyolipomaEUCTR2008-002113-48-NLovartis Pharma Services AG99
进行中（未招募）
1 期
Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer.HR+, HER2- advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2013-003084-61-SEovartis Pharma Services AG650
尚未招募
不适用
A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents.anti social behavior disorderaggressive behavior among chilren and adolescents with externalizing behavior problems.10037173NL-OMON38186niversitair Medisch Centrum Sint Radboud38